IONS Zilganersen PDUFA: Antisense Platform vs Alnylam

Ionis Pharmaceuticals closed Wednesday at $54.04. That is an $8.93 billion market cap for a company with $944 million in 2025 revenue and two FDA decisions coming in the next 60 days. Alnylam, the other RNA platform company, trades at $37 billion with a P/S ratio of 8.49. Ionis trades at approximately 9.5x revenue. Same technology class, same rare disease focus, less than a quarter of the market cap. On September 22, 2026, the FDA decides on zilganersen for Alexander disease. The drug itself is not the thesis. The platform is.

Alexander disease: the rarest of the rare

Alexander disease is a genetic leukodystrophy caused by mutations in the GFAP gene. Toxic overproduction of glial fibrillary acidic protein accumulates in astrocytes, the brain’s support cells, leading to progressive neurological deterioration. Patients lose the ability to walk, swallow, and control their airway. Death typically occurs 14 to 25 years after symptom onset. Prevalence is estimated at 1 per 2.7 million people, meaning roughly 500 diagnosed cases worldwide in the medical literature. There are zero approved disease-modifying treatments.

This is the definition of an ultra-rare disease. At $300,000 to $2 million per patient per year pricing, the addressable revenue is $150 million to $1 billion globally, depending on diagnosis rates and access. Even at the high end, zilganersen alone does not move Ionis’s $8.93 billion market cap. But that is the wrong way to value this asset.

The registrational trial: 54 patients, one endpoint

The registrational study (NCT04849741) is a Phase 1-3, randomized, double-blind, controlled trial. It enrolled 54 participants aged 1.5 to 53 years across 13 sites in 8 countries. Participants were randomized 2:1 to receive zilganersen or control for a 60-week double-blind treatment period. The primary endpoint was percent change from baseline in gait speed as measured by the 10-Meter Walk Test (10MWT) in patients aged 5 and older.

Results, presented at AAN 2026 in April:

• Primary endpoint met: zilganersen 50 mg demonstrated a 33.3% mean difference in gait speed versus control at Week 61 (p=0.0412). The drug stabilized or improved walking ability in a progressive disease where decline is the expected trajectory.
• Secondary endpoint in children aged 2-4: GMFM-88 gross motor function showed a 22.9-point difference favoring zilganersen (nominal p=0.034, not controlled for multiplicity).
• Biomarker confirmation: plasma GFAP levels decreased 33.6% at Week 61 versus control (nominal p=0.003), confirming the drug hits its molecular target.
• Safety: favorable. Most adverse events mild to moderate. Serious adverse events were numerically lower in the zilganersen arm versus control.

The FDA granted zilganersen Breakthrough Therapy designation, Orphan Drug designation, and Rare Pediatric Disease designation. The NDA was accepted for Priority Review with a PDUFA date of September 22, 2026.

The p-value of 0.0412 is the key risk factor. It barely cleared the 0.05 threshold. The trial had 54 patients in a rare disease with no approved comparator. The control arm was not a placebo in the traditional sense; it was a natural history-informed comparison. The FDA could question whether the single-arm registrational design and the natural history comparator provide sufficient evidence for approval. A CRL requesting confirmatory data is possible. But the Breakthrough Therapy designation and the biomarker confirmation (GFAP reduction correlated with clinical improvement) strengthen the filing.

The platform thesis

Here is why zilganersen matters beyond Alexander disease. Ionis is the antisense oligonucleotide platform. Every approval validates the platform’s economics. SPINRAZA (nusinersen), the company’s SMA drug partnered with Biogen, generated $356 million in Q4 2025 alone. WAINUA (eplontersen), partnered with AstraZeneca, generated $212 million in 2025 sales with $49 million in royalty revenue to Ionis. Tryngolza (olezarsen), Ionis’s first independent commercial launch, generated $108 million in 2025, its first year on market.

Ionis reported Q2 2026 earnings on July 30, with 2026 revenue guidance of $875 to $900 million. Two more FDA decisions are coming by October: zilganersen on September 22, and bepirovirsen (partnered with GSK for chronic hepatitis B) with a PDUFA of October 26. Bepirovirsen targets 250 million chronic HBV patients worldwide. GSK’s peak sales estimate exceeds £2 billion. Ionis earns royalties and milestone payments on that asset.

The comparison to Alnylam is the core valuation argument. Alnylam built the RNA interference (RNAi) platform. Ionis built the antisense oligonucleotide (ASO) platform. Both target RNA to treat genetic disease. Alnylam trades at $37 billion with a P/S of 8.49 and three approved products (Amvuttra, Oxlumo, Givlaari). Ionis trades at $8.93 billion with a P/S of 9.5 and a deeper pipeline including SPINRAZA royalties, WAINUA royalties, Tryngolza product sales, and two late-stage assets in zilganersen and bepirovirsen.

The P/S ratios are actually comparable: 8.49 for Alnylam versus 9.5 for Ionis. But Alnylam’s revenue base is larger and its market cap is 4.2x Ionis’s. If Ionis achieves two more approvals in the next 60 days, the revenue base grows and the platform narrative strengthens. Each approval narrows the market cap gap.

Competitive context for the platform

Ionis is not the only rare disease platform play, but it has the broadest pipeline. Sarepta dominates Duchenne muscular dystrophy with a $1.68 billion market cap and $2.2 billion in annual revenue. But Sarepta is a single-indication company. Ionis has approved drugs across SMA, ATTR amyloidosis, and FCS, with Alexander disease and hepatitis B pending. The diversity of the pipeline is what supports the platform multiple.

The best biotech stocks for 2026 catalysts ranked Ionis at number 5, citing the dual PDUFA catalysts. That ranking was made before the Q2 earnings confirmed the $875 to $900 million revenue guidance. With earnings out and both PDUFAs approaching, the setup is cleaner now than when the ranking was published.

Valuation

At $54.04 per share and 165 million shares outstanding, Ionis has an $8.93 billion market cap. The 2026 revenue guidance of $875 to $900 million implies a forward P/S of 9.9 to 10.2. That is in line with Alnylam’s 8.49. If zilganersen is approved and launches at $500,000 per patient per year with 200 US patients diagnosed, that adds $100 million in annual revenue at steady state, likely by 2028. If bepirovirsen is approved in October, Ionis earns tiered royalties on GSK’s commercial sales, estimated at 10 to 15% of net sales. At £2 billion peak, that is $200 to $300 million in annual royalty revenue.

Combined, zilganersen and bepirovirsen could add $300 to $400 million in annual revenue by 2028. That would bring Ionis to $1.2 to $1.3 billion in revenue, supporting a market cap of $10 to $12 billion at a 9x P/S multiple. The upside from $8.93 billion to $12 billion is 34%. The downside from a CRL on zilganersen alone, with bepirovirsen still pending, is probably 15 to 20%.

The PDUFA date for zilganersen is September 22, 2026. A Priority Review Voucher from the Rare Pediatric Disease designation could be awarded upon approval, adding $100 to $150 million in value if sold. That is a bonus, not the thesis.

Risks

The specific risk is the p-value. At p=0.0412, the primary endpoint barely met significance. The FDA has approved drugs on marginal p-values in ultra-rare diseases with no alternatives, especially with Breakthrough Therapy designation and biomarker confirmation. But the agency has also issued CRLs for single-arm trials with natural history comparators when the effect size was modest. The 33.3% gait speed improvement is clinically meaningful in a progressive disease, but the FDA’s standard for functional endpoints in neurology is high. The Q3 2026 FDA calendar includes several rare disease PDUFAs, and the agency’s appetite for single-arm data varies by division.

The second risk is commercial. Even with approval, Alexander disease has 500 diagnosed cases globally. Launching a drug for an ultra-rare disease requires specialized distribution, patient identification, and payer education. Ionis has done this with Tryngolza for FCS, but the FCS population is larger and more defined.

The third risk is the bepirovirsen dependency. If bepirovirsen receives a CRL on October 26, the platform narrative weakens and the stock likely gives back any zilganersen approval gains. Two binary events in 60 days means high volatility.

Verdict

Approval probability for zilganersen: 75%. The Breakthrough Therapy designation, biomarker confirmation, and favorable safety profile outweigh the marginal p-value. But 25% CRL risk is real for a single-arm trial with p=0.0412.

Stock impact: 10 to 15% upside on approval, 20 to 25% downside on CRL. The stock is a binary bet on two PDUFAs in 60 days. If both approve, IONS moves toward $65 to $70 as the platform narrative closes the gap with Alnylam. If zilganersen approves and bepirovirsen CRLs, the stock is range-bound at $54. If both CRL, the stock tests $42 to $45.

Position: Buy a half position ahead of September 22. The platform thesis is real. The valuation gap with Alnylam is real. But the binary risk of two CRLs in 60 days is too high for a full position. Scale in after the first PDUFA resolves. If zilganersen approves, add on any pullback before October 26. The antisense platform has produced SPINRAZA, WAINUA, plus Tryngolza. Two more approvals in 60 days would give Ionis five commercialized or partnered assets across SMA, ATTR amyloidosis, FCS, Alexander disease, and hepatitis B. No other rare disease platform has that breadth. That is the thesis. The p-value is the risk.